Portal Hypertension Management Market Will Generate Booming Growth Opportunities to 2033

Posted by Ganesh Shinde on February 15th, 2023

The global Portal Hypertension Management Market is predicted to be valued at US$ 3.05 billion in 2023, with a CAGR of 5% from 2023 to 2033. The market for portal hypertension management is expected to reach .97 billion by the end of the forecast period.

One of the most common causes of portal hypertension is cirrhosis. Cirrhosis is a type of liver disease that is characterised by scar tissue that replaces healthy liver cells. As a result, the increase in the number of persons affected by this ailment is expected to fuel market expansion. Males are more likely than females to get cirrhosis, according to the National Institute of Diabetes and Digestive and Kidney Diseases Trusted Source. As a result, it is projected that the elderly would contribute to market growth.

Because of high-cost technological advances in the health-care system and a rise in the prevalence and frequency of beta-blocker ingestion, North America has the biggest market share. Because of its expanding older population and higher diagnosis rate, Asia-Pacific has the second-largest market revenue. As the prevalence and occurrence of rare diseases, as well as the inpatient population, continue to expand, North America is predicted to account for the majority of the market in the future decade.

The expansion of the Liver Transplantation segment can be linked to the global increase in demand for transplantable organs. According to the US Department of Health and Human Services, around 122,913 diagnoses were ready for organ transplants in the United States in 2019. As a result, transplantation items produced for organ damage intervention are in high demand. As a result, the Liver Transplantation market is rising.

Competitive Landscape

Key players in the Portal Hypertension Management market areOno Pharmaceutical Co., Ltd., Chiasma, Inc., Genextra S.p.a., Gilead Sciences, Inc., Debiovision, Inc., Govind Ballabh Pant Hospital, Dr. Falk Pharma GmbH, Novartis AG, Sun Pharmaceuticals Industries Ltd.

Get More Details@ https://www.futuremarketinsights.com/reports/portal-hypertension-management-market

Key Segments Profiled in the Portal Hypertension Management Industry Survey

By Treatment:

• Liver Transplantation
• Endoscopic Therapy
• Banding
• Balloon Tamponade
• Shunting Procedures
• Nonsurgical Transjugular Intrahepatic Portal Systemic Shunt
• Surgical Shun
• Drug Class
• Octapeptides
• Cofactors
• PDE5 Inhibitor
• Beta Blockers

By End Users:

• Hospitals
• Specialty Clinic
• Others